CN-121987649-A - Application of ammonium glycyrrhetate in preparing medicine for treating lacrimal gland secretion dysfunction related diseases

Abstract

The application is a divisional application of application number 2025116336025. The application provides application of ammonium glycyrrhetate in preparing a medicament for treating lacrimal gland secretion dysfunction related diseases, relates to the technical field of biomedicine, constructs a lacrimal gland dysfunction dry eye mouse model, and intervenes by adopting liposome-entrapped ammonium glycyrrhetate, and experimental results show that the ammonium glycyrrhetate treatment remarkably improves the functions and structures of the ocular surface of a model animal, the cornea sodium fluorescein staining score of mice in an ammonium glycyrrhetate treatment group is remarkably reduced, the cornea epithelial damage is effectively repaired, the epithelial layer structure in cornea tissue tends to be complete, inflammatory cell infiltration of a stroma layer is remarkably reduced, and the goblet cell density in conjunctiva is remarkably improved, so that the secretion function of an ocular surface mucous layer is recovered. And ammonium glycyrrhetate treatment has a trend toward improvements in tear film break-up time and tear secretion, indicating its potential role in maintaining tear film stability and promoting basal tear secretion.

Inventors

• ZHU YUJUAN
• GU ZHIFENG
• TAO XINYU
• CHEN MINJIE
• ZHAO RUI

Assignees

• 南通大学附属医院

Dates

Publication Date

20260508

Application Date

20251110

Claims (4)

1. 1. Application of ammonium glycyrrhizate in preparing medicine for treating lacrimal gland secretion dysfunction related diseases is provided.
2. 2. The use of ammonium glycyrrhizate according to claim 1 for the preparation of a medicament for the treatment of disorders related to lacrimal gland secretion dysfunction, characterized in that the disorders related to lacrimal gland secretion dysfunction include dry eye.
3. 3. A medicine for treating diseases related to lacrimal gland secretion dysfunction is characterized in that the medicine contains ammonium glycyrrhizate.
4. 4. The medicine for treating lacrimal gland secretion dysfunction related diseases according to claim 3, wherein the medicine further comprises pharmaceutically acceptable carrier or adjuvant.

Description

Application of ammonium glycyrrhetate in preparing medicine for treating lacrimal gland secretion dysfunction related diseases The application relates to a coordinate axis organoid chip for high-flux in-situ tracking drug screening and a construction method thereof, which are divisional applications of China application application of 2025, 11, 10 and 2025116336025. Technical Field The invention relates to the technical field of biomedicine, in particular to application of ammonium glycyrrhetate in preparing a medicament for treating diseases related to lacrimal gland secretion dysfunction. Background Dry eye is the most common ocular disease in ophthalmic consultation except ametropia, and is mainly manifested by insufficient tear secretion or excessive tear evaporation, leading to dryness, irritation and inflammation of the ocular surface. Although traditional treatment methods (such as artificial tears, anti-inflammatory drugs, etc.) can alleviate symptoms, it is often difficult to fundamentally repair damaged ocular surface tissues, and frequent use is required, and patient compliance is poor. Thus, the search for effective and alternative therapeutic interventions is critical to meeting urgent medical needs. In terms of drug screening for dry eye, traditional 2D cells and animal models have far failed to meet their practical needs. The establishment of new experimental medical models and research modes has important significance for deep understanding of the pathogenesis of xerophthalmia and developing effective therapeutic measures. Disclosure of Invention The invention aims to solve the problem that effective treatment measures for xerophthalmia are lacking in the prior art. In order to achieve the above purpose, the present invention adopts the following technical scheme: Application of ammonium glycyrrhizate in preparing medicine for treating lacrimal gland secretion dysfunction related diseases is provided. Preferably, the disorders associated with dysfunction of lacrimal gland secretion include dry eye. The application also provides a medicine for treating diseases related to lacrimal gland secretion dysfunction, and the medicine comprises ammonium glycyrrhetate. Preferably, the medicament also comprises a pharmaceutically acceptable carrier or auxiliary material. Compared with the prior art, the application has the following beneficial effects: The research constructs a lacrimal gland dysfunction dry eye mouse model, and adopts liposome-entrapped ammonium glycyrrhizate for intervention. Analysis of multiple physiological and histological indexes shows that the ammonium glycyrrhetate treatment can obviously improve the functions and structures of the ocular surface of the model animal. Drawings FIG. 1 is a bright field image of a lacrimal gland organoid stimulated with the monomeric ammonium glycyrrhetate of the traditional Chinese medicine showing its morphological changes and secretion-related response in an embodiment of the invention. FIG. 2 is a photograph of a sodium corneal fluorescein stain of a dry eye mouse treated with liposome-coated ammonium glycyrrhizate showing improvement of corneal epithelial damage in accordance with one embodiment of the present invention. Fig. 3 is a representative image of conjunctival sac and cornea area of a dry eye mouse treated with liposome-coated ammonium glycyrrhetate in accordance with one embodiment of the present invention, further demonstrating the protective effect of the drug on ocular surface tissue. FIG. 4 is a graph showing the comparison of tear film rupture time and tear secretion after ammonium glycyrrhetate treatment according to an embodiment of the present invention, wherein the left graph shows tear film rupture time and the right graph shows tear secretion. Detailed Description The present invention will be described in further detail with reference to specific examples. 1. Experimental materials and sources 1. Engineered liposome preparation 2. Animal experiment 1. Example 1 verifies the use of ammonium glycyrrhetate, the chemical formula of which is shown below, in the preparation of a medicament for treating diseases related to lacrimal gland secretion dysfunction: Preparation of (one) Liposomes (LNP) 1. Preparation of lipid films: D-Lin-MC3-DMA, distearoyl-sn-glycero-3-phosphorylcholine (DSPC), polyethylene glycol 2000 (PEG 2000) and cholesterol were accurately weighed according to a molar ratio of 50:10:1.5:38.5, ensuring a total mass of 1 mg. The above lipid material was dissolved in 500. Mu.L of chloroform as an organic solvent, and stirred well to dissolve the lipid completely. Transferring the dissolved lipid solution into a rotary evaporator, and performing rotary evaporation at 40 ℃ to remove the organic solvent to form a uniform lipid film. The lipid film after rotary evaporation was placed in a vacuum oven and dried for a further 2 hours to ensure complete removal of residual organic solvent. 2. And (3) hydration treatment